MENUNews Archive
Date: 06/19/2024
A brief recap of Rogel Cancer Center researcher presentations at ASCO 2024 in Chicago.
Date: 06/12/2024
Researchers at the University of Michigan are finding that many patients may be encountering significant barriers to cancer care, even from their first phone call to a clinic.
Date: 06/12/2024
Diffuse intrinsic pontine glioma, or DIPG, is the most aggressive pediatric brain tumor and incredibly difficult to treat since surgery isn’t feasible and recurrence is likely after radiation. This research may provide some insight.
Date: 06/06/2024
According to preliminary findings from a survey led by Rogel researcher Steven Katz, M.D., MPH, a professor of health management and policy, the ability to fully realize genetic testing among family members of patients is mitigated by several factors.
Date: 06/03/2024
Research findings show that a process called NETosis, in which neutrophils eject their DNA to create webs, may contribute to the development of cytokine release syndrome (CRS), a potentially life-threatening hyper-activation of the immune system.
Date: 05/30/2024
The University of Michigan Rogel Cancer Center has awarded four Michigan community organizations a total of $200,000 in grants for projects designed to improve cancer screening and tobacco cessation among populations experiencing cancer disparities. The grants will enable each organization to implement evidence-based interventions within the community they serve.
Date: 05/22/2024
Check out the list of U-M presenters to support your colleagues. Connect with researchers on X/Twitter using #AACR24. Be sure to tag @UMRogelCancer.
Date: 05/06/2024
Do all thyroid cancer survivors need the same level of follow-up care and monitoring? With a new $3.3 million grant from the National Cancer Institute, Megan Haymart, M.D., will identify survivors at different risks of recurrence and develop a system for long-term monitoring based on that risk.
Date: 04/29/2024
University of Michigan Rogel Cancer Center researcher Arul Chinnaiyan, M.D., Ph.D., has received a $5 million grant from the J.C. Kennedy Foundation to conduct laboratory tests of a potential drug candidate targeting a master regulator that controls the majority of genes involved in the most challenging type of prostate cancer.
Date: 04/11/2024
By combining data from MRI scans and clinical tests, University of Michigan Rogel Cancer Center researcher Chuan Zhou, Ph.D., will develop a decision support tool to tailor treatment for individual patients with multiple myeloma. It’s a cancer that’s considered incurable, with survival ranging from less than a year to more than a decade, depending on the extent and aggressiveness of the tumors.